Press releases and news
2021
Change in number of shares and votes in Camurus
Camurus’ Interim Report Second Quarter 2021
Change in number of shares and votes in Camurus
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
Change in number of shares and votes in Camurus
Exercise of Camurus’ subscription warrant program 2018/2021
Camurus receives Carnegie Sustainability Award 2021
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
Resolutions at the annual general meeting 2021 in Camurus
Camurus’ Interim Report January-March 2021
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence
Camurus Annual Report for 2020
Notice of annual general meeting 2021 in Camurus AB (publ)
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence
Camurus’ Full Year Report 2020
Change in number of shares and votes in Camurus
Camurus appoints Andrew McLean as Vice President Corporate Development and Senior Counsel
2020
Change in number of shares and votes in Camurus
Swissmedic approves Buvidal for the treatment of opioid dependence
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.